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There is strong evidence indicating a role for ceramide as a second messenger in processes such as apoptosis, cell growth and differentiation,
and cellular responses to stress. Ceramide formation from the hydrolysis of sphingomyelin is considered to be a major pathway of stress-induced
ceramide production with magnesium-dependent neutral sphingomyelinase (N-SMase) identified as a prime candidate in this pathway. The recent
cloning of a mammalian N-SMase–nSMase2- and generation of nSMase2 knockout/mutant mice have now provided vital tools with which to
further study the regulation and roles of this enzyme in both a physiological and pathological context. In the present review, we summarize current
knowledge on N-SMase relating this to what is known about nSMase2. We also discuss the future areas of nSMase2 research important for
molecular understanding of this enzyme and its physiological roles.
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Since the discovery that sphingosine inhibited protein kinase
C (PKC) in 1986 [1], the sphingolipids have emerged as
important lipid second messengers. In particular, there is
considerable evidence showing a role for ceramide, the
precursor to all complex sphingolipids (and to sphingosine),
in the cellular responses to stress, cell growth and differentia-
tion, and apoptosis (programmed cell death). The sphingomye-
linases (SMases) produce ceramide from the hydrolysis of
sphingomyelin and have been implicated as a major pathway of
stress-induced ceramide production. Consequently, the
extended family of sphingomyelinases has captured great
interest and has evolved into an area of active research.
Currently, five types of SMases have been identified/recog-
nized—the ubiquitous lysosomal acid SMase, the zinc-
dependent secreted acid SMase, a neutral, Mg2+-dependent
SMase, a neutral Mg2+-independent SMase and an alkaline
SMase (reviewed in [2,3]). Of these, the lysosomal acidic
SMase and the Mg2+-dependent neutral SMase have emerged
as the prime candidates for stress-induced ceramide responses.
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doi:10.1016/j.bbamem.2006.06.025research on the neutral isoform was hampered by the lack of a
purified or cloned isoform—something that was rectified
within the last few years. In this review, we summarize current
knowledge on neutral SMase (N-SMase) activity, and relate this
to what is currently known about the cloned N-SMase enzymes.
We also discuss major directions for N-SMase research.
2. Neutral Sphingomyelinase (N-SMase): from discovery to
purification
Neutral sphingomyelinase activity was first described by
Schneider and Kennedy in 1967 who found that the spleens of
patients with Niemann–Pick disease (deficient in acid SMase)
contained a Mg2+-dependent enzyme capable of carrying out
the same reaction that had an optimum pH of 7.4 [4]. N-
SMase activity was further characterized in crude extracts of
human grey matter where it was found to be predominantly
membrane-bound [5] and highly present in brain and, to a
lesser extent, spleen and liver. Furthermore, the differing
characteristics of acid and N-SMase suggested they were two
distinct enzymes, and the subsequent measuring of N-SMase
activity in acid SMase knockout mice confirmed that the two
proteins were also separate gene products [6]. Subsequent
research found that N-SMase activity was induced by a variety
of stimuli such as cytokines, cellular stresses such as UV light
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amyloid-β peptides and lipopolysaccharide [2,7]. That N-
SMase is activated by such a wide range of stimuli further
highlights the importance of the enzyme as a regulator of
ceramide-dependent signaling. It is also now known that N-
SMase is part of a larger family that includes Isc1 from Sac-
charomyces cervisiae and the bacterial SMases from Bacillus
cereus and Leptspira interrogans.
It was some three decades after the describing of N-SMase
activity before the first purification of mammalian N-SMase
from rat brain [8] and bovine brain [9]. This resulted in
enzymes with similar characteristics to the described activity,
being stimulated by phosphatidylserine, dependent on divalent
cations such as Mg2+ and with an optimum pH of 7.4.
Subsequent work in bovine brain reported N-SMase activities
with different biochemical and chromatographical properties,
thus suggesting the existence of multiple N-SMase isoforms
[10].
3. Regulation of neutral sphingomyelinase activity
Despite the lack of a cloned or purified mammalian N-SMase
until recent years, considerable research into the regulation of
N-SMase activity has been carried out, leading to the
identification of various factors that influence the stimulation
of N-SMase activity (Fig. 1).Fig. 1. Current knowledge of N-SMase compared to nSMase2. (A) A number of studi
regulators and suggested physiological roles of N-SMase activity. (B) Emerging ev
emerging roles on possible physiological and pathophysiological roles of the enzym3.1. Oxidative stress
A strong body of literature indicates a link between
activation of N-SMase and oxidative stress. This connection
was first suggested by a study reporting that physiological
concentrations of the tripeptide antioxidant glutathione (GSH)
inhibited N-SMase activity [11] and it was subsequently found
that GSH depletion was necessary for TNF-stimulated N-SMase
activation in MCF-7 cells [12]. However, as the oxidative
activation of N-SMase by GSH depletion was inhibited by Bcl-
XL, this suggested that the regulation was indirect [13]. The
connection between oxidative stress and N-SMase was
reinforced in a number of studies. The stimulation of PC12
cells with hydrogen peroxide or hypoxia resulted in formation
of reactive oxygen species (ROS) and activation of N-SMase
[14,15]. Also, treatment of both rat mesangial cells and HL-60
cells with nitric oxide donors resulted in increased ceramide
levels and cell death [16,17]. Finally, overexpression of the
enzyme glutathione peroxidase 1 prevented the generation of
ROS and subsequent activation of the SM-ceramide pathway in
cells treated with doxirubin and anti-CD95 [18,19].
More recent research has also implicated the plasma
membrane redox system as a regulator of N-SMase activity.
The reduced form of coenzyme Q (ubiquinol) is considered a
major component of this system, protecting against peroxida-
tion and maintaining the reduced forms of exogenouses into N-SMase (total activity) have led to the identification of many activators,
idence on the mechanisms of nSMase2 activation and regulation, and possible
e.
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exogenous ubiquinol and reduction of endogenous ubiquine
to ubiquinol was able to regulate the plasma membrane-
associated N-SMase activity, preventing both ceramide
accumulation and caspase-3 activation in response to serum
withdrawal [20]. These results were recently complemented by
an in vivo study reporting that rats on a polyunsaturated fatty
acid diet supplemented with coenzyme Q10 exhibited
decreased membrane-associated N-SMase activity and
enhanced lifespan [21]. However, whilst the evidence indicates
a strong link between the oxidative state of a cell and the
regulation of N-SMase activity, the specific mechanisms of
how this occurs in vivo are not yet known.
3.2. Lipids
The activation of N-SMase by phosphatidylserine is well-
established in the partially purified proteins from rat and
bovine brain [8,9]. Additionally, studies have reported the
activation of N-SMase by polyunsaturated fatty acids (PUFA)
[22] and arachidonic acid although in the latter case, this
appears to be upstream of glutathione depletion [23].
Interestingly, a recent in vivo study in mice found that dietary
supplementation of omega-3 PUFA attenuated breast cancer
growth through activation of an N-SMase pathway [24]
suggesting that the lipid regulation of N-SMase is of
physiological relevance.
3.3. Receptor-mediated regulation
Studies into the activation of N-SMase by external receptors
have focused strongly on the 55 kDa receptor for TNF-α. A
region of this receptor adjacent to the death domain was
specifically required for activation of N-SMase through the
binding of a novel adaptor protein—factor associated with N-
SMase activation or FAN [25]. The importance of FAN was
subsequently confirmed in studies showing that overexpression
enhanced TNF-stimulated N-SMase activity whereas truncated
FAN mutants had dominant negative effects [26], a role also
confirmed in FAN-deficient mice [27]. Whilst the mechanisms
coupling FAN to N-SMase activation are unclear, more recent
work has implicated RACK-1 and caveolin-1 as positive and
negative modulators of N-SMase activity respectively [28,29].
3.4. Other regulatory factors
Other research has also suggested additional factors as
regulators of N-SMase activity. There is some evidence for
cross-talk between the ceramide and protein kinase C (PKC)
pathways with studies reporting regulatory effects of ceramide
on activity and localization of PKC-α [30], PKC-δ [31] and
PKC-ζ [32]. Consistent with this, there is also some evidence of
PKC regulation of N-SMase. In mesangial cells, the cytokine-
induced activation of an N-SMase was prevented by stimula-
tion with phorbol esters—with such inhibition reversed by
inhibitors of PKC [33]. Additionally, the redox-dependent N-
SMase activity stimulated by chemotherapeutic drugs in U937cells was inhibited by overexpression of PKC-ζ [34]. Finally, a
study in HL-60 cells reported that activation of N-SMase by
1,25-dihydroxyvitamin D3 was mediated by PKC-α and
inhibited by PKC-δ—although this is in reference to the
cytosolic Mg2+-independent N-SMase [35].
The involvement of N-SMase in apoptosis (see below) also
led to investigating where N-SMase is positioned in the
apoptotic protease cascade. Previous studies from our laboratory
have suggested that the enzyme was upstream of the effector
caspases such as caspase-6, -9 or -3 but downstream of the
initiator caspases such as caspase-8 [36,37]. This agrees with
other studies placing N-SMase upstream of caspase-3 and other
executor caspases such as in hypoxia-exposed PC12 cells [15]
and apoptosis stimulated by heat shock in HL-60 cells [38].
However, a recent study in TNF-α-stimulated rat hepatoma
cells reported that a dominant-negative FAN mutant inhibited
activation of the initiator caspase 8 [39]. This could potentially
place caspase 8 below N-SMase activity although an alternative
possibility that would correlate with previous research is that
caspase 8 could lie between FAN and N-SMase. Furthermore,
there are some studies that have reported executor caspase-
mediated regulation of N-SMase. Inhibition of caspase 3
prevented nitric oxide-stimulated N-SMase activity in HL-60
cells [40] and caspase-9 appeared to be upstream of N-SMase in
LNCaP cells stimulated with etoposide [41] suggesting that
effector caspases can also regulate N-SMase as well. This is also
consistent with a recent study of knockout mice lacking both
caspase-3 and -7 reporting a positive feedback role for effector
caspases on the initial components of the apoptotic pathway
[42]. Moreover, as N-SMase-mediated apoptosis has been
reported in MCF-7 cells that lack caspase-3 [36], it is plausible
that the position of the enzyme in the protease cascade is
specific to both cell type and apoptotic stimuli.
4. Roles of neutral sphingomyelinase activity
4.1. Apoptosis
Programmed cell death is an essential and closely regulated
process important for development and normal tissue home-
ostasis. The role of ceramide as an important mediator of
apoptosis is well-established, and data have implicated SMase-
mediated ceramide production as a major pathway involved in
this process [43,44], a theory supported by the activation of N-
SMase in response to a number of apoptotic stimuli including
cytokines, heat stress and serum starvation [7]. Evidence first
suggesting the involvement of N-SMase in the apoptotic
response came from the linking of GSH depletion – observed
in response to many apoptotic stimuli – to activation of N-
SMase as discussed above [11] and from the N-SMase-
mediated activation of Ras and subsequent apoptosis in Fas-
activated T cells [45]. Subsequent work implicated activation
of N-SMase in TNF-stimulated cell death [46] and found that
this was upstream of mitochondrial changes, cytochrome C
release and caspase-9 activation in MCF-7 cells [36]. A recent
study in rat hepatoma cells reported that N-SMase is even
further upstream in apoptotic signaling as dominant-negative
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and release of cathepsin B into the cytosol [39]. However,
although the evidence for a role for N-SMase in apoptotic
signaling is strong, it is also clear that it acts in concert with
other signals to modulate cell death [46,47].
4.2. Cell growth
A number of studies have established a role for ceramide in
regulating the cell cycle and mediating growth arrest [48],
possibly through dephosphorylation of retinoblastoma protein
(Rb) and/or regulation of cyclin dependent kinases [49,50].
Research has also suggested possible roles of N-SMase in this
process. Serum withdrawal in Molt-4 cells caused activation
of N-SMase and cell cycle arrest at G0/G1 [51] and the
activation of N-SMase was suggested to be involved in
telomerase inhibition and cell cycle arrest induced by
daunorubicin [52].
4.3. Inflammation
There is now strong evidence for a role of sphingolipids in
inflammatory responses such as prostaglandin production,
upregulation of adhesion proteins and leukocyte recruitment
[53]. Whilst ceramide itself appears not to be a direct regulator
of these pathways, it is now well understood that the important
second messengers involved are sphingosine-1-phosphate and
ceramide-1-phosphate—both downstream metabolites of cer-
amide. While research has focused largely on ceramide kinase
and sphingosine kinase—the enzymes directly responsible for
producing these lipids, little work has investigated the
upstream source of the ceramide used in these pathways. A
study in NCI-H292 cells reported that TNF-α-stimulated
COX-2 induction was inhibited by GSH [54]. Additionally,
recent work in our laboratory found that downregulation of
acid SMase with siRNA had no effect on TNF-α-stimulated
COX-2 induction or PGE2 production in L929 fibroblasts (Y.
Zaidan and Y.A. Hannun, unpublished observations). Taken
together, these data raise the possibility that an N-SMase
activity could be involved in the inflammatory response to
cytokines.
5. Cloning of mammalian nSMases
The first nSMase enzyme – nSMase1 – was cloned from
murine and human sources in 1998 by pursuing mammalian
homology to bacterial neutral SMases [55]. However, although
the enzyme possessed an in vitro Mg2+-dependent N-SMase
activity, subsequent research found that overexpression of the
enzyme had no effect on SM metabolism but significantly
reduced levels of lyso-PAF, suggesting that it functioned as a
lyso-PAF phospholipase C [56–58]. The lack of in vivo SMase
activity of the enzyme was further confirmed in nSMase1
knockout mice that had neither lipid storage abnormalities nor
deficient SMmetabolism [59]. Interestingly, these mice also had
unperturbed lyso-PAF levels and so the function of nSMase1
remains something of a mystery.6. Neutral Sphingomyelinase 2
Two years after the cloning of nSMase1, a second
mammalian enzyme with an in vitro Mg2+-dependent N-
SMase activity was cloned and termed nSMase2 [60]. More
importantly, research characterizing this enzyme found that
nSMase2 also possessed in vivo N-SMase activity when
overexpressed in Isc1-deleted yeast. Furthermore, stable over-
expression of the enzyme in mammalian cells resulted in
significant effects on SM and ceramide levels, thus confirming
its function as both an in vivo and in vitro N-SMase [61].
However, the relatively recent conformation of this enzyme as
an in vivo N-SMase implies that there are very few studies on
this enzyme in the literature and these broadly focus on the
physiological roles of nSMase2.
7. Neutral Sphingomyelinase 3
Recently, the cloning and characterization of a novel
mammalian N-SMase was reported by Kronke and coworkers
[62]. Named nSMase3, this enzyme corresponded to the
previously purified enzyme from bovine brain [9] and,
although they share little homology, nSMase3 did have very
similar characteristics to nSMase2 [62]. Interestingly, nSMase3
mRNA was predominantly expressed in heart and skeletal
muscle raising the possibility of specific roles of nSMase3 in
heart function and possibly the pathogenesis of cardiac
diseases. The cloning of a second mammalian N-SMase is
consistent with previous reports suggesting the existence of
multiple N-SMase isoforms [10] and further highlights that
there is considerable research to be performed in order to
obtain a clearer picture of the roles of this pathway in
physiological and pathological contexts. Additionally, this may
also account for discrepancies between previously reported
functional roles of N-SMase activity in comparison to those
attributed to nSMase2.
8. NSMase inhibitors
Many studies into the physiological roles of N-SMase have
utilized pharmacological inhibitors, and a number of different
compounds are in common use having been reported as
inhibitors of N-SMase. Scyphostatin, a chemical isolated from
Discomycetes was shown to inhibit N-SMase activity and cell
death in neurons [63]. 3-O-methylsphingomyelin, a SM
analogue reduced LPS-stimulated iNOS expression in glial
cells whereas acid SMase or de novo ceramide synthesis
inhibitors had no effect [64]. GW4869 was reported to
function as a noncompetitive inhibitor with SM and prevented
TNF-α-stimulated cell death in MCF-7 cells [36]. C11AG
selectively suppressed N-SMase activity in T-cells and
macrophages [65]. Finally, manumycin A significantly
decreased TNF-stimulated N-SMase activity in HUVEC
cells [66] although it is also known as an inhibitor of Ras
farnesyltranferase. A major problem with these compounds is
that, aside from GW4869, their activity on the cloned isoform
nSMase2 has not been investigated. Additionally, there may
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compounds, particularly in the case of analogues such as 3-O-
methylsphingomyelin. However, now that siRNA to nSMase2
has been developed and is readily available [66,67], this
provides a more accurate and specific tool for investigating
roles of the enzyme. Thus, for future research, we suggest that
such pharmacological inhibitors of N-SMase should be used
with caution and in conjunction with RNAi or cells derived
from knockout/mutant mice.
9. Roles and targets of nSMase2
One of the first studies on nSMase2 reported the confluence-
induced upregulation of nSMase2 activity and mRNA. This
resulted in the hypophosphorylation of Rb protein and induction
of p21/WAF-1 – both regulators of the cell cycle – and lead to
growth arrest of cells in the G0/G1 phase. We also observed a
confluence-induced translocation of nSMase2 to the plasma
membrane suggesting that translocation may be an important
step to bring the enzyme into contact with its substrate [67].
This involvement of nSMase2 in growth arrest is consistent
with previous studies implicating N-SMase activity in this and
the cell cycle as discussed above. Even more interestingly, a
study focusing on genes upregulated during confluence arrest
had previously identified nSMase2 as a confluence-arrest gene,
CCA1, in rat 3Y1 cells [68].
Further insight into the downstream effects of nSMase2 has
come from the Karakashian group who utilized adenovirus
transfection of primary hepatocytes to study the role of N-
SMase in interleukin-1β (IL-1β)-stimulated JNK activation.
They reported that overexpression of nSMase2 was able to
enhance basal and IL-1β-stimulated JNK phosphorylation in a
manner dependent on the ceramide-activated protein phospha-
tase PP2A. It was further speculated that this was due to effects
on the phosphorylation of the IL-1β receptor-associated kinase
(IRAK)—a key modulator of IL-1β signaling [69].
A more recent study by the Clementi group has provided
further evidence implicating nSMase2 in the endothelial
response to TNF-α. Using a HUVEC cell model, they found
that TNF induced a rapid and sequential activation of nSMase2
and sphingosine kinase 1 leading to production of sphingosine-
1 phosphate (S1P). This led to activation of endothelial nitric
oxide synthase (eNOS) through activation of S1P receptors
[66]. The biological relevance of this pathway is evident from
the crucial role of nitric oxide as a regulator of endothelial
physiology and its involvement in inflammatory processes [70].
9.1. Amyloid-β Peptides
A number of studies have provided evidence implicating N-
SMase in the pathogenesis of Alzheimer's disease (AD)
through amyloid-β (Aβ) peptide, a cleavage product of
amyloid precursor protein [71]. Studies have reported that Aβ
is toxic to neurons, vascular smooth muscle cells, endothelial
cells and oligodendrocytes [72–75]. Subsequent research in
oligodendrocytes and neurons demonstrated that this was due
to oxidative activation of N-SMase. In these studies, it wasshown that Aβ peptides led to enhanced activity of N-SMases,
decreased levels of sphingomyelin and increased levels of
ceramide. These effects were inhibited by preventing the
formation of intracellular reactive oxygen species elicited by
Aβ peptides. More significantly both pharmacologic and RNAi
inhibitors of nSMase2 inhibited the cytotoxic effects of Aβ
peptides [76–80]. Interestingly, a recent study reported the
stimulation of N-SMase by Aβ42 in a cell-free assay without
other modulating factors inferring a direct interaction between
the two proteins [81]. This tantalizing result requires direct
validation. Furthermore, additional evidence has suggested that
N-SMase may amplify responses through feedback regulation
of Aβ peptide levels as the nSMase2 inhibitor GW4869
decreased both secreted and intracellular Aβ levels [81]. This
could be through an nSMase2-mediated decrease in SM levels
and/or through production of ceramide, reported to enhance Aβ
peptides production in CHO cells [81,82]. Taken together, these
studies offer compelling evidence that nSMase2 plays an
important role in the pathogenesis of AD and could be a useful
therapeutic target in the future.
9.2. nSMase2 knockout mice
A major achievement of recent years has been the generation
of nSMase2 knockout mice and the identification of a
spontaneous mutation in a muse model of osteogenesis
imperfecta—undoubtedly important research tools. The knock-
out mice were developed by the Stoffel group by the disruption
of exon 1 of the nSMase2 gene. Unlike acid SMase null mice,
these animals had no deficiency in lipid storage but unexpect-
edly developed growth retardation as embryos—as much as
50% less than wild type that remained throughout development.
This retardation was most visibly manifested in the skeletonwith
the long bones found to have short stature and deformation [83].
Interestingly, an independent study of a mouse model of
osteogenesis and dentinogenesis imperfecta (the fro/fro mouse)
found that the mutated allele localized to the nSMase2 gene
(Smpd3) and resulted in a deletion of the C-terminal 33 amino
acids of the enzyme—including a histidine residue crucial for
activity. The mice with the fro mutation had normal cartilage but
severely undermineralized bones [84]. Although it is tempting
to speculate that this phenotype can be attributed solely to the
lack of nSMase2 activity, it is also a possibility that additional,
unidentified defects may account for the osteogenesis imper-
fecta phenotype. However, the fact that both these mutant mice
and the nSMase2 knockout mice have related phenotypes
(albeit clearly distinct) suggests that nSMase2 has an important
role to play as a regulator of bone formation and/or
development. Interestingly, these processes rely heavily on
TNF and TNF-related cytokines such as RANKL.
10. Ongoing and future directions of N-SMase research
Despite the number of studies on the regulation and roles of
N-SMase activity in a variety of cell lines and tissues, research
was hampered by the lack of a specific purified or cloned
enzyme. The cloning of nSMase2 and the generation of
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biochemical tools for further research. In this section, we will
briefly discuss the major unknown areas of N-SMase that need
to be addressed in the near future.
10.1. Regulatory mechanisms
Despite the evidence in the literature tying N-SMase activity
to oxidative stress, receptor-mediated regulation through FAN
and other pathways such as PKC and the protease cascade, there
is a scarcity of information on how these factors influence N-
SMase directly—something that can now be investigated further
with the cloned enzyme. With both oxidative stress and FAN,
evidence suggests that regulation of N-SMase is indirect and
likely involves other intermediate effectors such as Bcl-XL [13],
RACK [28], caveolin-1 [29] or proteases. It is now possible to
investigate direct interactions or co-localization between these
or other putative regulators and nSMase2 and, more importantly,
what consequences such interactions may have for N-SMase
activation. Furthermore, the stimulation of N-SMase activity by
such a wide number of stimuli offers a number of models with
which to study the regulation of nSMase2—and particularly to
determine if the regulatory mechanisms are common or vary
according to the physiological context.
Our previous observation that confluence induces a transloca-
tion of intracellular nSMase2 to the plasma membrane suggests
that localization of the enzyme could also be an important aspect
of its regulation by restricting access to substrate. Thus, the
translocation of nSMase2 to a sphingomyelin-rich membrane
such as the plasmamembranemay be a necessary step for bothN-
SMase activation and function. In our laboratory, we have been
further exploring regulation of nSMase2 and found that phorbol
esters induce a similar translocation of nSMase2 to the plasma
membrane in subconfluent cells in a time- and dose-dependent
fashion (C.J. Clarke and Y.A. Hannun, unpublished observation)
consistent with a role for PKC as an upstream regulator of N-
SMase activity as described above.
10.2. Aspects of nSMase2
Following on from the biochemical characterization of
nSMase2 and confirmation of its in vivo activity, very little
about the enzyme itself is known. Whilst nSMase2 is known to
contain a collagenous domain positioned between the putative
transmembrane segments and the catalytic region, the function
of this domain has yet to be investigated. Additionally, the
activation of nSMase2 by anionic phospholipids suggests the
existence of a phospholipid-binding domain that could have
potential consequences for enzyme localization, as phosphati-
dylserine and cardiolipin, both shown to bind to nSMase2, are
enriched in the plasma membrane and mitochondria, respec-
tively. There is also the possibility of other protein-binding
domains or regulatory motifs within the enzyme. Indeed, we
have recently identified two recycling endosome motifs in
nSMase2—a dileucine motif and a tyrosine motif (reviewed in
[85]). Furthermore, mutation of key residues in these domains
to alanine resulted in an enzyme that was constitutively presentat the plasma membrane and a decrease in N-SMase activity (T.
G. Truong and Y.A. Hannun, unpublished observations). Thus,
an understanding of the domain and motif structure of nSMase2
could shed light on how nSMase2 activity and localization are
regulated.
There is also a limited understanding of the topology of
nSMase2 beyond the original predicted structure of two
transmembrane segments and a C-terminal catalytic domain.
This may be of particular importance when considering the
localization of substrate, product, and potential downstream
targets of N-SMase-produced ceramide. This, in turn, may shed
light on the downstream pathways regulated by nSMase2.
10.3. Physiological roles
Activation of N-SMase has been reported in response to a
number of stimuli and has been implicated in a variety of
processes as discussed above. This offers a number of potential
physiological models with which to study the signaling
pathways regulated by nSMase2. Whilst the published work
on nSMase2 has begun to address the downstream targets of
nSMase2-generated ceramide, the development of knockout
mice now provides a valuable tool with which to consolidate
existing observations with in vivo experiments. Furthermore,
the knockout mice can be used to direct research at the
mechanistic and cellular level as they may offer unexpected and
unusual phenotypes that will warrant further exploration.
11. Conclusions
There is a growing literature on the activation, regulation
and roles of N-SMase activity in various cells and tissues and in
response to a wide number of stimuli. The cloning of a
mammalian N-SMase – nSMase2 – and generation of
nSMase2 knockout mice now provides major tools for future
research. A major focus of this research should be to bridge the
gaps between the established knowledge of N-SMase activity
and the cloned enzyme, further elucidating the specific
mechanisms of regulation, downstream targets and physiologi-
cal roles of nSMase2. In understanding the physiological
context of N-SMase activation, it might then be possible to
understand how dysregulation of the enzyme may occur in
pathological conditions—and ultimately allow the develop-
ment of therapeutic intervention.
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